SEC Form 4 · accession 0001193805-16-002401
ADMA BIOLOGICS, INC. · ADMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam S Grossman
Officer — President & CEO · Director
Period of report
Jan 28, 2016
Accepted (ET)
Feb 1, 2016 · 7:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001368514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchaseF1,F2 | $5.96 | Jan 28, 2016 | A | 16,984 | A | — | Jan 28, 2026 | Common Stock | 16,984 | 16,984 | D |
Explanation of responses
- F1The exercise price reflects the per share fair market value of the Company's common stock, as determined by the closing price of the Company's common stock on the NASDAQ Stock Market on January 28, 2016, the date that the option grant was approved by the Company's board of directors.
- F2These options vest over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years.